secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001493152-26-014654
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off
-------------------------------------------------------------------------

- Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).
- Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.
- Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.
- Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.
- Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer